Screener / SEC EDGAR /CIK 0000310764 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Stryker Corporation SYK

Compare with peers Embed
New in the 10-K - Risk Factors could not be compared with last year's 10-K New in the 10-Q 15 paragraphs not in the 10-Q filed Jul 31, 2026 10-Q against the 10-K 0 risk factor paragraphs and sentences added or reworded

Paragraphs with nothing like them in last year's 10-K

Risk Factors could not be compared with last year's 10-K, so new paragraphs are not counted. The sections that were compared are under 10-K change.

Paragraphs in the 10-Q filed Oct 30, 2026 that were not in the one before

New in the latest 10-Q

15 paragraphs in the 10-Q filed Oct 30, 2026 with nothing like them in the 10-Q filed Jul 31, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

We test goodwill annually for impairment at October 31 or whenever events or circumstances indicate that goodwill may be impaired. During the third quarter 2026, various factors indicated it was more likely than not that the carrying value of our Peripheral Vascular reporting unit exceeded its fair value. As a result, we performed an interim impairment assessment of goodwill, indefinite-lived and other long-lived assets of the Peripheral Vascular reporting unit and a charge of $ 293 was recognized in goodwill and other impairments in the Consolidated Statements of Earnings. The impairment amount represents the excess of the carrying value of the Peripheral Vascular reporting unit over its fair value, which we estimated using an income-based valuation approach.

Read in the 10-Q

The impairment charge for the Peripheral Vascular reporting unit was primarily driven by a reduction in forecasted cash flows reflecting near-term operational and supply constraints and a longer expected period to achieve anticipated growth and market recovery. Significant inputs to the analysis included assumptions for future revenue growth, operating margin, the effective tax rate applied to future earnings and the rate used to discount the estimated future cash flows to their present value, based on the reporting unit’s estimated weighted average cost of capital.

Read in the 10-Q

Future changes in the judgments, assumptions and estimates that are used in our impairment testing for goodwill, including discount and tax rates and future cash flow projections, could result in significantly different estimates of the fair values. A significant reduction in the estimated fair values could result in impairment charges that could materially affect our results of operations.

Read in the 10-Q

In October 2026 we signed an agreement with CMR Surgical, a global robotics company and maker of the Versius Plus surgical robot, to invest approximately $ 400 in cash in exchange for CMR Surgical's preferred equity. The agreement grants us exclusive U.S. distribution rights for the Versius portfolio and an exclusive option to acquire 100 % of CMR Surgical's remaining outstanding equity in the future. The transaction is expected to close in the fourth quarter 2026, subject to regulatory approval and customary closing conditions.

Read in the 10-Q

Termination of sales relationships in certain countries 37 2 Spinal Implants sale related 77 9

Read in the 10-Q
Show the other 10

was approximately 44% on September 30, 2026 compared to 20% on December 31, 2025.

Read in the 10-Q

We test goodwill annually for impairment at October 31 or whenever events or circumstances indicate that goodwill may be impaired. When it is unlikely that goodwill of a reporting unit is impaired, we perform a qualitative assessment that may be periodically supplemented with a corroborative quantitative analysis.

Read in the 10-Q

The Peripheral Vascular business’s operating results have been affected by a reduction in forecasted cash flows reflecting near-term operational and supply constraints and a longer expected period to achieve anticipated growth and market recovery. These inputs were included in the updated projections used in our annual long-range financial plan, which was approved during the third quarter 2026. As a result of these factors, we performed an interim impairment assessment of goodwill, indefinite-lived and other long-lived assets of the Peripheral Vascular reporting unit and a charge of $293 was recognized in goodwill and other impairments in the Consolidated Statements of Earnings.

Read in the 10-Q

Goodwill attributable to the Peripheral Vascular reporting unit was approximately $3,259 at September 30, 2026.

Read in the 10-Q

In our interim quantitative goodwill impairment test, the fair value of our Peripheral Vascular reporting unit was determined using a discounted cash flow analysis, which is a form of the income approach. Significant inputs to the analysis included assumptions for future revenue growth, operating margin, the effective tax rate applied to future earnings and the rate used to discount the estimated future cash flows to their present value based on the reporting unit’s estimated weighted average cost of capital. Our assumptions for revenue growth and operating margin considered several operating factors, including supply constraints and our competitive environment. We believe our estimates are appropriate based upon current and future market conditions and the best information available at the impairment assessment date; however, future impairment charges could be required if our Peripheral Vascular reporting unit does not achieve its cash flow, revenue and profitability projections or if there is an increase in the weighted average cost of capital.

Read in the 10-Q

The assumptions used in the discounted cash flow analysis are subject to inherent uncertainties and subjectivity. The use of different assumptions, estimates or judgments with respect to the estimation of future cash flows and the determination of the discount rate used to reduce such estimated future cash flows to their net present value could materially affect the determination of any impairment charges. Hypothetical changes in our estimates of the discount rate, long-term revenue growth and long-term operating margin would result in incremental impairment charges as follows:

Read in the 10-Q

Share sales and buybacks

In 2026 we repurchased 3 million shares of our common stock at a cost of $1,000 under our authorized share repurchase program. The total dollar value of our shares of common stock that could be acquired under our authorized repurchase program was $33 as of September 30, 2026.

Read in the 10-Q

Other information

Disclosure Pursuant to Section 13(r) of the Exchange Act Section 13(r) of the Exchange Act requires an issuer to disclose in its annual or quarterly reports whether it or any of its affiliates knowingly engaged in certain activities, transactions or dealings relating to parties subject to sanctions administered by the Office of Foreign Assets Control (OFAC) within the United States Department of the Treasury, whether or not such activities are prohibited or sanctionable under United States law. On March 2, 2021 the United States government designated the Russian Federal Security Service (FSB) under additional sanctions authorities. On the same day, OFAC issued General License No.

Read in the 10-Q

1B (OFAC General License) which generally authorizes certain licensing, permitting, certification, notification and related transactions with the FSB as may be required pursuant to Russian encryption product import controls for the importation, distribution or use of certain information technology products and radio frequency technology products in the Russian Federation. As required under Russian law and as permitted under the OFAC General License one of our subsidiaries in Russia periodically files notifications with or applies for import licenses and permits from the FSB on our behalf in connection with the importation of our products into Russia. These notification and licensing activities are free of charge and none of our gross revenue or net profits are attributable to such activities. We expect to continue to file notifications with and apply for import licenses and permits from the FSB to qualify our products for importation and distribution in the Russian Federation to the extent required under Russian law but only so long as such notification and licensing activities are authorized by the OFAC General License, any successor general license or other authorization issued by OFAC.

Read in the 10-Q

During the three months 2026 we filed three notifications with the FSB as described above.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Oct 30, 2026 against Item 1A of the 10-K filed Feb 11, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:We are not aware of any material changes to the risk factors included in Item 1A. "Risk Factors" in our Annual Report on Form 10-K for 2025 and Part II, Item 1A. "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Read in the 10-Q

1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.

What was taken out

65 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
We are subject to pricing pressures as a result of cost containment measures in the United States and other countries and other factors, including changes in reimbursement practices and coverage policies and third-party payor cost containment measures: Initiatives to limit the growth of general healthcare expenses and hospital costs are ongoing in the markets in which we do business. These initiatives are sponsored by government agencies, legislative bodies and the private sector and include price regulation and competitive pricing. For example, China has implemented a volume-based...
In the 10-K filed Feb 12, 2025
We use a variety of raw materials, components, devices and third-party services in our global supply chains, production and distribution processes; significant shortages, price increases or unavailability of third-party services have in the past increased, and could in the future increase, our operating costs and could require significant capital expenditures or adversely impact the competitive position of our products: Our reliance on certain suppliers to secure raw materials, components and finished devices, and on certain third-party service providers, such as sterilization service...
In the 10-K filed Feb 12, 2025
We are subject to extensive governmental regulation relating to the classification, manufacturing, sterilization, licensing, labeling, marketing and sale of our products: The classification, manufacturing, sterilization, licensing, labeling, marketing and sale of our products are subject to extensive and evolving regulations and rigorous regulatory enforcement by the FDA, state governments, European Union and other governmental authorities in the United States and internationally. These governmental authorities may impose additional requirements or limits on the methods, procedures or...
In the 10-K filed Feb 12, 2025
We are subject to privacy, data protection and data security regulations and laws globally, and could face substantial penalties if we fail to comply with such regulations and laws: We are subject to a variety of laws and regulations globally regarding privacy, data protection, and data security, including those related to the collection, storage, handling, use, disclosure, transfer and security of personally identifiable healthcare information. For example, in the United States, privacy and security regulations under the Health Insurance Portability and Accountability Act of 1996,...
In the 10-K filed Feb 12, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SYK/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.